Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Orelabrutinib with Rifampin or Itraconazole in Healthy Subjects
NCT05316857Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orelabrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by InnoCare Pharma. Primary endpoint: Maximum Plasma Concentration up to 3 months. Started Dec 2021; status: completed.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05316857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316857.